• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    2/11/22 11:19:49 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTI alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

                

    British American Tobacco PLC


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G1510J102


    (CUSIP Number)

    December 31, 2021


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G1510J102

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital International Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 110,384,647
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 110,680,543
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    110,680,543 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.8%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    British American Tobacco PLC
    (b) Address of Issuer's Principal Executive Offices
    Globe House, 4 Temple Place, London, GL WC2R 2PG, United Kingdom
    Item 2.
    (a) Name of Person Filing
    Capital International Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G1510J102
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    110,680,543 **
    (b) Percent of Class:
    4.8%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 110,384,647
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 110,680,543
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., and Capital Group Private Client Services, Inc. (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 110,680,543 shares or 4.8% of the 2,294,686,147 shares believed to be outstanding.

    Shares reported include 8,748,112 Depository Receipts, which represent 8,748,112 Common Stock.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital International Investors
    By: /s/ Walter R. Burkley
    Date: February 14, 2022
    Name: Walter R. Burkley
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $BTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTI

    DatePrice TargetRatingAnalyst
    4/30/2025Buy
    BofA Securities
    1/27/2025Neutral → Buy
    UBS
    10/3/2024$33.00Overweight → Underweight
    Morgan Stanley
    1/23/2024Neutral
    UBS
    11/1/2023$38.00Overweight
    Morgan Stanley
    9/25/2023Buy
    Citigroup
    9/1/2023Buy → Hold
    Argus
    3/13/2023Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BTI
    SEC Filings

    See more
    • SEC Form 6-K filed by British American Tobacco Industries p.l.c.

      6-K - British American Tobacco p.l.c. (0001303523) (Filer)

      5/9/25 11:07:44 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by British American Tobacco Industries p.l.c.

      6-K - British American Tobacco p.l.c. (0001303523) (Filer)

      5/6/25 12:33:01 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by British American Tobacco Industries p.l.c.

      6-K - British American Tobacco p.l.c. (0001303523) (Filer)

      5/1/25 7:49:52 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Financials

    Live finance-specific insights

    See more
    • Charlotte's Web Reports 2024 First Quarter Financial Results

      LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

      5/8/24 7:07:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charlotte's Web Reports 2023 Second Quarter Financial Results

      Encouraging CBD regulatory progress in CongressNet revenue of $16.0M vs. $18.9M YoYCash increased to $61.7M LOUISVILLE, Colo., Aug. 10, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the second quarter ended June 30, 2023.  Regulatory Update During the second quarter, the U.S. Food and Drug Administration ("FDA") committed to "work at speed" with Congress to resolve a regulatory pathway for hemp-derived CBD.

      8/10/23 7:33:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charlotte's Web Reports 2023 First Quarter Financial Results

      Net cash of $61MNet revenue of $17M decreased 12.1% YoY14% YoY reduction in operating expenses LOUISVILLE, Colo., May 12, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2023. "In the first quarter, we maintained prudent cost controls to balance softness in the CBD category due to the unregulated environment. We successfully reduced operating expenses by 14% on a year-over-ye

      5/12/23 7:05:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charlotte's Web Reports 2024 First Quarter Financial Results

      LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

      5/8/24 7:07:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

      1/24/24 6:21:08 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Organigram Announces C$124.6 Million Investment from BAT and Creation of "Jupiter" Strategic Investment Pool

      Organigram and BAT deepen partnership through C$124.6 million investment with 38.7 million shares to be issued over three tranches Organigram to use C$83.1 million of the investment to create "Jupiter," a strategic investment pool designed to expand Organigram's geographic footprint and capitalize on emerging growth opportunities C$41.5 million of the investment will be used for general corporate purposes Investment enhances strategic Product Development Collaboration between BAT and Organigram, which focuses on cutting-edge R&D and product innovation BAT to increase voting Common Share ownership position to 30% and overall equity interest to 45% (including non-voting Class A P

      11/6/23 6:00:00 AM ET
      $BTI
      $OGI
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BTI
    Leadership Updates

    Live Leadership Updates

    See more
    • British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

      1/24/24 6:21:08 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charlotte's Web Announces Appointment of Bill Morachnick as Chief Executive Officer

      Provides Update on Majority Voting Policy Process LOUISVILLE, Colo., Sept. 13, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") is pleased to announce the appointment of William (Bill) Morachnick who has joined the Company as its Chief Executive Officer. Mr. Morachnick has also been appointed to the Company's Board of Directors as a non-independent director. He replaces CEO Jacques Tortoroli who has elected to resign from his roles at Charlotte's Web.  CWEB) (OTCQX:CWBHF):. The World's Most Trusted Hemp Extract and Official CBD of Major League Baseball (MLB). (C

      9/13/23 7:07:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • GREENBUTTS APPPOINTS FORMER BIG TOBACCO EXECUTIVE AS CHIEF STRATEGY OFFICER

      SAN DIEGO, Calif., June 22, 2022 /PRNewswire/ - Greenbutts, LLC (the "Company" or "Greenbutts") is pleased to announce the appointment of Luis Sanches as the Company's Chief Strategy Officer effective immediately. Luis is a Senior Corporate Executive with more than 30 years of international, cross functional and cross-cultural experience responsible for managing business teams, supporting growth, and leading transformations across multiple geographies such as Australasia, North and South America, and Europe. He was previously the Senior Vice President of R&D for Reynolds Ameri

      6/22/22 2:34:00 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

      SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

      2/9/24 6:03:23 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

      SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

      2/9/24 5:46:32 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

      SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

      1/26/24 4:56:06 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on British American Tobacco

      BofA Securities resumed coverage of British American Tobacco with a rating of Buy

      4/30/25 9:01:21 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • British American Tobacco upgraded by UBS

      UBS upgraded British American Tobacco from Neutral to Buy

      1/27/25 7:35:54 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • British American Tobacco downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded British American Tobacco from Overweight to Underweight and set a new price target of $33.00

      10/3/24 7:24:54 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Bt De Investments Inc.

      3 - British American Tobacco p.l.c. (0001303523) (Reporting)

      11/23/22 4:29:54 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care